Key Details
Price
$10.99Annual Revenue
$151.00 KAnnual ROE
-50.19%Beta
1.41Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 6, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK CITY, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NASDAQ:KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/KROS.
NEW YORK CITY, NY / ACCESS Newswire / January 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NASDAQ:KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/KROS.
NEW YORK, NY / ACCESS Newswire / January 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQ:KROS) concerning possible violations of federal securities laws. Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial.
FAQ
- What is the ticker symbol for Keros Therapeutics?
- Does Keros Therapeutics pay dividends?
- What sector is Keros Therapeutics in?
- What industry is Keros Therapeutics in?
- What country is Keros Therapeutics based in?
- When did Keros Therapeutics go public?
- Is Keros Therapeutics in the S&P 500?
- Is Keros Therapeutics in the NASDAQ 100?
- Is Keros Therapeutics in the Dow Jones?
- When was Keros Therapeutics's last earnings report?
- When does Keros Therapeutics report earnings?
- Should I buy Keros Therapeutics stock now?